Growth Factor News and Research

RSS

Pancreatic stellate cells help pancreatic cancer grow and spread in cell hijack method

Pancreatic stellate cells, which normally aid tissue repair, unwittingly help pancreatic cancer grow and spread in a method of 'cell hijack' only seen before in brain and breast cancer, according to new research from Queen Mary University of London.

10 Feb 2014

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

5 Feb 2014

Findings expand treatment options for hormone-dependent breast cancer

According to the United States Centers for Disease Control and Prevention, breast cancer is the most common cancer in women. For patients whose breast cancers are hormone-dependent, current treatment focuses on using drugs that block estrogen (a type of hormone) from attaching to estrogen receptors on tumor cells to prevent the cells from growing and spreading.

5 Feb 2014

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.

4 Feb 2014

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

The once sketchy landscape of the molecular defects behind bladder cancer now resembles a road map to new, targeted treatments thanks to the unified efforts of scientists and physicians at 40 institutions.

30 Jan 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

South Korean lung SCC genetic secrets revealed

Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say.

27 Jan 2014

Novel HER2 mutation identified in familial lung adenocarcinomas

Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas.

24 Jan 2014

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

Consider two drivers, each with a key that fits the same car. Driver 1 wants simply to turn on the ignition and leave the vehicle idling, ready and waiting to roll. Driver 2 wants to take it on a destructive joy ride.

24 Jan 2014

Lack of SIRT1 protein in the liver leads to lower levels of liver FGF21

A new study led by Boston University School of Medicine demonstrates that the abnormal metabolism linked to obesity could be regulated in part by the interaction of two metabolic regulators, called the NAD-dependent deacetylase SIRT1 and fibroblast growth factor 21 (FGF21). Using experimental models, the researchers found that a lack of SIRT1 protein in the liver led to lower levels of a liver secreted protein FGF21, which resulted in an increased likelihood of developing fatty liver disease and obesity.

22 Jan 2014

UT Southwestern' faculty receives Stanley J. Korsmeyer Award for contributions to understanding of autophagy

Dr. Beth Levine, a Howard Hughes Medical Institute Investigator and Director of the Center for Autophagy Research at UT Southwestern Medical Center, has received the 2014 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation.

22 Jan 2014

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.

21 Jan 2014

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

Smoking, diets rich in animal products, alcohol have correlations with cancer incidence rates, says study

A multicountry study just published in Nutrients finds that smoking, diets rich in animal products, and alcohol have the strongest correlations with cancer incidence rates. The cancer incidence rates are from 2008 as assembled by the International Agency for Research on Cancer of the World Health Organization.

28 Dec 2013

Combination of NGF microspheres and chitosan conduits exhibit better effects in repairing facial nerve injury

The chitosan molecule can promote nerve cell adherence and growth along the surface of the material. It can enhance the adherence and influx of Schwann cells, thus encouraging the growth of axons.

28 Dec 2013

Study shows beneficial effects of normobaric oxygen on cerebral ischemic injury

Normobaric oxygen has the rapid and non-invasive characteristics and may have therapeutic effects on ischemic/hypoxic disease.

28 Dec 2013

Hypoxic preconditioning has protective effects against acute cerebral infarction

Hypoxic preconditioning has been shown to have protective effects against acute cerebral infarction. To investigate the protective mechanisms of hypoxic preconditioning in relation to its effects on angiogenesis, Prof. Xunming Ji and team from Xuanwu Hospital, Capital Medical University in China induced a photochemical model of cerebral infarction in an inbred line of mice (BALB/c) which were exposed to hypoxic preconditioning prior to model establishment.

24 Dec 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs. The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.

18 Dec 2013

Growth Factor News and Research

Pancreatic stellate cells help pancreatic cancer grow and spread in cell hijack method

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Findings expand treatment options for hormone-dependent breast cancer

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

Everolimus fails to boost advanced NSCLC response

South Korean lung SCC genetic secrets revealed

Novel HER2 mutation identified in familial lung adenocarcinomas

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

Lack of SIRT1 protein in the liver leads to lower levels of liver FGF21

UT Southwestern' faculty receives Stanley J. Korsmeyer Award for contributions to understanding of autophagy

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

No added benefit from aflibercept, shows study

Smoking, diets rich in animal products, alcohol have correlations with cancer incidence rates, says study

Combination of NGF microspheres and chitosan conduits exhibit better effects in repairing facial nerve injury

Study shows beneficial effects of normobaric oxygen on cerebral ischemic injury

Hypoxic preconditioning has protective effects against acute cerebral infarction

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News